Patentscope RSS feed

Methods of in-vitro analysis using time-domain NMR spectroscopy (Thu, 03 Sep 2009)
An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.
>> Read More

Methods of in vitro analysis using time-domain NMR spectroscopy (Thu, 17 Apr 2008)
An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.
>> Read More

Methods of in-vitro analysis using time-domain NMR spectroscopy (Thu, 21 Jul 2011)
An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.
>> Read More

METHODS OF IN VITRO ANALYSIS USING TIME-DOMAIN NMR SPECTROSCOPY (Thu, 20 Jul 2006)
An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD- NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.
>> Read More

IDENTIFICATION OF INSECT ATTRACTANT, ARRESTING, AND/OR AGGREGATION COMPOUNDS AND METHODS THEREOF (Thu, 01 Dec 2011)
Compounds, compositions, kits, devices, and methods of attracting, detecting, eradicating, controlling, or killing an insect, such as a bed bug, by utilizing insect attractant, arresting, and/or aggregation compounds and compositions is provided. Insect attractant, arresting, and/or aggregation compounds identified from insect fecal extract by an analytical technique, such as gas chromatography, nuclear magnetic resonance (NMR), Carbon-13 NMR, mass spectroscopy, LC-MS, GC-MS, high performance liquid chromatography (HPLC), or combinations thereof are provided. A bed bug attractant, arresting, and/or aggregation compound identified from bed bug feces and exhibiting a Carbon-13 NMR peak at about d 159.453 ppm is also provided.
>> Read More

Method and apparatus for the determination of the individual mass flow rates of a multicomponent flow (Wed, 10 Jan 1996)
The apparatus consists of an arrangement of several magnets for fluid polarization and several NMR or EMR flow sensors aligned along a pipeline (10). The method is based on the fact that the individual components of the multi-component flow have different products of longitudinal relaxation time T1 and flow velocity v. In the preferred and illustrated embodiment, a static magnetic field H0 is imposed on the multi-component flow by means of a suitable magnet arrangement. In this magnet arrangement, the linear movement of the flow generates a multi-exponential gain of magnetization along the pipeline. By interrogating the multi-component flow at several positions in the magnet arrangement with suitable pulse techniques magnetization and velocity is measured simultaneously at several positions in the magnet arrangement. The gathered data permits reconstruction of the multi-exponential gain of magnetization and the determination of the equilibrium magnetization of each component in thermal equilibrium. This magnetization is a measure of the mass of each component present in the flow. Together with fluid velocity, this allows the determination of the mass flow rates of the individual components of the flow.
>> Read More

Crystalline modification of CDCH, process for its preparation and pharmaceutical compositions containing it (Wed, 25 Jun 1997)
1-Cyclopropyl-7-((S,S)-2,8-diazabicycloÄ4,3,0Ünon-8-yl)-6-fluoro-1,4-d ihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride (CDCH) monohydrate of formula (I) Äin a prismatic crystalline formÜ having a characteristic <13>C NMR peak at 168.1 ppm and an X-ray diffraction band at 2Theta = 26.7 is new.
>> Read More

IDENTIFICATION OF INSECT ATTRACTANT, ARRESTING, AND/OR AGGREGATION COMPOUNDS AND METHODS THEREOF (Thu, 01 Dec 2011)
Compounds, compositions, kits, devices, and methods of attracting, detecting, eradicating, controlling, or killing an insect, such as a bed bug, by utilizing insect attractant, arresting, and/or aggregation compounds and compositions is provided. Insect attractant, arresting, and/or aggregation compounds identified from insect fecal extract by an analytical technique, such as gas chromatography, nuclear magnetic resonance (NMR), Carbon-13 NMR, mass spectroscopy, LC-MS, GC-MS, high performance liquid chromatography (HPLC), or combinations thereof are provided. A bed bug attractant, arresting, and/or aggregation compound identified from bed bug feces and exhibiting a Carbon-13 NMR peak at about δ 159.453 ppm is also provided.
>> Read More

POLYURETHANE POLYOLEFINS AND PREPOLYMERS BASED ON HYDROXY FUNCTIONAL POLYBUTADIENE (Tue, 29 Jun 1999)
A di-hydroxy-functionalized linear non-crosslinked polyolefin is disclosed having no pendant chain-branched groups which is prepared by reacting 1,4-diacetoxy-2-butene with 1,5-cyclooctadiene in the presence of a catalyst comprising a ruthenium metal carbene complex, characterized in that the functionality number of said polyolefin as determined by NMR is 2.0 and the viscosity of said polyolefin ranges from about 800 to 16000 mPa.cndot.s @25°C at a number average molecular weight ranging from 2,600 to 6,500 g/mole. A prepolymer comprising the reaction of a polyisocyanate with the polyolefin is also disclosed.
>> Read More

Polyurethane polyolefins and prepolymers based on hydroxy functional polybutadiene (Tue, 23 Nov 1999)
A di-hydroxy-functionalized linear non-crosslinked polyolefin is disclosed having no pendant chain-branched groups which is prepared by reacting 1,4-diacetoxy-2-butene with 1,5-cyclooctadiene in the presence of a catalyst comprising a ruthenium metal carbene complex, characterized in that the functionality number of said polyolefin as determined by NMR is 2.0 and the viscosity of said polyolefin ranges from about 800 to 16000 mPa.s @25.degree. C. at a number average molecular weight ranging from 2,600 to 6,500 g/mole. A prepolymer comprising the reaction of a polyisocyanate with the polyolefin is also disclosed.
>> Read More

Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy (Thu, 20 Mar 2003)
The invention relates to conjugates comprised of macrocyclic metal complexes with biomolecules and to the production thereof. The conjugates are suited for use as contrast agents in NMR diagnosis and radiodiagnosis and as agents for radiotherapy. A high relaxivity is achieved and a fine tuning of the relaxivity is made possible by a special liganding of the macrocycles.
>> Read More

Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman (Wed, 28 May 1997)
A new crystalline form (Ia) of (R)-(-)-2-(N-(4-(1,1-dioxido-3-oxo-2,3-dihydro-2-benzisothiazolyl)buty l)aminomethyl)-chroman hydrochloride (I) is new and characterised Äin subsidiary claimsÜ by its heat of transformation (24 J/g at 60 degrees C), X-ray diffraction data, IR spectrum, solid-phase <13>C-NMR spectrum, FIR spectrum and Raman spectrum.
>> Read More

CONJUGATES OF MACROCYCLIC METAL COMPLEXES WITH BIOMOLECULES AND THE UTILIZATION THEREOF FOR PRODUCING AGENTS FOR USE IN NMR DIAGNOSIS AND RADIODIAGNOSIS AND RADIOTHERAPY (Fri, 09 Apr 2004)
The invention relates to conjugates comprised of macrocyclic metal complexes with biomolecules and to the production thereof. The conjugates are suited for use as contrast agents in NMR diagnosis and radiodiagnosis and as agents for radiotherapy. A high relaxivity is achieved and a fine tuning of the relaxivity is made possible by a special liganding of the macrocycles. © KIPO & WIPO 2007
>> Read More

Metal chelates having a perfluorinated peg group, method for the production thereof, and use thereof (Thu, 11 Jun 2009)
The invention relates to the subject matters characterized in the claims, namely metal chelates having a perfluorinated PEG group, a method for the production thereof, and the use thereof, a method for the production thereof, and the use thereof in NMR and radiology diagnostics, radio diagnostics, and radio therapy, and in MRI lymphography.
>> Read More

Efomycin G and it's use as yield promoter in animals (Tue, 22 May 1990)
An animal growth promoter, efomycin G, is obtained by culturing Streptomycetes strain BS 1261. Efomycin G has the following properties: PA0 (a) The empirical formula: C.sub.53 H.sub.86 O.sub.18 PA0 (b) The mass spectrum (fast atom bombardment) Molecular weight+Na.sup.+ : 1033 PA0 (c) The .sup.1 H-nuclear magnetic resonance spectrum, stated in parts per million, shown in FIG. 1. PA0 (d) The .sup.13 C-nuclear magnetic resonance spectrum, stated in parts per million shown in FIG. 2, with chemical shifts of the CC-NMR signals as follows: TBL ______________________________________ 170.0 77.9 65.9 32.9 7.0 145.4 73.4 48.5 19.4 144.7 71.2 43.6 19.1 131.9 70.6 41.9 16.8 121.1 70.1 41.1 16.7 99.6 69.9 38.8 15.1 99.5 66.9 38.5 13.4 93.6 66.5 36.2 9.0 93.3 66.4 33.0 8.9 ______________________________________ (ppm values are relative to tetramethylsilane at 0 ppm) PA0 (e) A UV absorption maximum at 251-254 nm in methanolic solution PA0 (f) The structure according to FIG. 3.
>> Read More

Detection of magnetised fluid flows (Wed, 24 Aug 1994)

>> Read More

Complexes containing perfluoroalkyl, method for the production and use thereof (Thu, 13 Mar 2008)
The invention relates to objects which are characterised in the claims, that is, metal complexes containing perfluoroalky, comprising radicals of general formula I containing nitrogen, to a method for the production and use thereof in the NMR field and x-ray diagnosis, radiodiagnosis and radiotherapy, in addition to lymphography in the MRT field and for blood pool imaging.
>> Read More

PERFLUOROALKYL-CONTAINING COMPLEXES, PROCESS FOR THEIR PRODUCTION AS WELL AS THEIR USE (Thu, 25 Jan 2007)
The invention relates to objects which are characterised in the claims, that is, metal complexes containing perfluoroalky, comprising radicals of general formula I containing nitrogen, to a method for the production and use thereof in the NMR field and x-ray diagnosis, radiodiagnosis and radiotherapy, in addition to lymphography in the MRT field and for blood pool imaging.
>> Read More

COMPLEXES CONTAINING PERFLUOROALKYL, METHOD FOR THE PRODUCTION AND USE THEREOF (Mon, 19 May 2008)
The invention relates to objects which are characterised in the claims, that is, metal complexes containing perfluoroalky, comprising radicals of general formula I containing nitrogen, to a method for the production and use thereof in the NMR field and x-ray diagnosis, radiodiagnosis and radiotherapy, in addition to lymphography in the MRT field and for blood pool imaging. ©KIPO&WIPO 2008
>> Read More

PERFLUOROALKYL-CONTAINING COMPLEXES, PROCESS FOR THEIR PRODUCTION AS WELL AS THEIR USE (Thu, 25 Jan 2007)
The invention relates to the objects which are characterised in the patent claims, that is, metal complexes which contain perfluoroalkyl having N-alkyl groups of general formula (I), to a method for the production thereof and to the use thereof in NMR and X-ray diagnosis, radiodiagnosis and radiotherapy, and in MRT lymphography.
>> Read More